A. Swift

560 total citations
10 papers, 479 citations indexed

About

A. Swift is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, A. Swift has authored 10 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cell Biology. Recurrent topics in A. Swift's work include Advanced Breast Cancer Therapies (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Cancer-related Molecular Pathways (2 papers). A. Swift is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Cancer-related Molecular Pathways (2 papers). A. Swift collaborates with scholars based in United States, France and Spain. A. Swift's co-authors include Carolyn E. Machamer, Melissa G. Grim, Kathleen R. Ryan, Melissa M. Rolls, Sarina A. Piha‐Paul, Alessandra Tosolini, Olav Dajani, Antoine Hollebecque, Guillem Argilés and Shiva Gupta and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Annals of Oncology.

In The Last Decade

A. Swift

10 papers receiving 462 citations

Peers

A. Swift

MB

CB

ID

ASZ

ONCOL

Barbara K. Timblin United States

Lynn Plowright United Kingdom

Daniela Gamba Italy

Samantha L. Schwartz United States

Dandan Jiang China

S. Anna La Rocca United Kingdom

Alistair R. McNab United States

Diego Guerrera Switzerland

Heli Matilainen Finland

Vasker Bhattacherjee United States

Barbara K. Timblin United States

A. Swift

298 ×1.0

MB

225 ×1.0

CB

78 ×1.0

ID

23 ×0.4

ASZ

27 ×0.6

ONCOL

Citations per year, relative to A. Swift A. Swift (= 1×) peers Barbara K. Timblin

Countries citing papers authored by A. Swift

Since Specialization

Citations

This map shows the geographic impact of A. Swift's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Swift with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Swift more than expected).

Fields of papers citing papers by A. Swift

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Swift. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Swift. The network helps show where A. Swift may publish in the future.

Co-authorship network of co-authors of A. Swift

This figure shows the co-authorship network connecting the top 25 collaborators of A. Swift. A scholar is included among the top collaborators of A. Swift based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Swift. A. Swift is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Machiels, J-P., Ezra E.W. Cohen, Kevin J. Harrington, et al.. (2015). 343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial. Annals of Oncology. 26. ix93–ix93. 1 indexed citations

2.

Piha‐Paul, Sarina A., P.N. Munster, Antoine Hollebecque, et al.. (2015). Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. European Journal of Cancer. 51(14). 1865–1873. 63 indexed citations

3.

Gupta, Supriya, Antoine Hollebecque, Guillem Argilés, et al.. (2014). Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence. Annals of Oncology. 25. i25–i25. 1 indexed citations

4.

Machamer, Carolyn E., et al.. (1993). Retention of a cis Golgi protein requires polar residues on one face of a predicted alpha-helix in the transmembrane domain.. Molecular Biology of the Cell. 4(7). 695–704. 63 indexed citations

5.

Swift, A., et al.. (1993). Oligomerization of a membrane protein correlates with its retention in the Golgi complex. The Journal of Cell Biology. 122(6). 1185–1196. 134 indexed citations

6.

Swift, A. & Carolyn E. Machamer. (1991). A Golgi retention signal in a membrane-spanning domain of coronavirus E1 protein.. The Journal of Cell Biology. 115(1). 19–30. 169 indexed citations

7.

Swift, A., Steve Davidson, & A E Berger. (1988). Phosphorylation of a Mr 70,000 protein is associated with interleukin 2 receptor expression.. Journal of Biological Chemistry. 263(5). 2389–2396. 3 indexed citations

8.

Rodway, R. G. & A. Swift. (1983). Melatonin and the Pituitary Response to GnRH in Prepubertal and Adult Ewes. Hormone and Metabolic Research. 15(7). 349–351. 4 indexed citations

9.

Kennedy, William P., A. Swift, Richard F. Parrish, & K. L. Polakoski. (1982). Proacrosin conversion inhibitor. Purification and initial characterization of a boar sperm protein which prevents the conversion of proacrosin into acrosin.. Journal of Biological Chemistry. 257(6). 3095–3099. 11 indexed citations

10.

Swift, A., et al.. (1974). The chemistry of human hair cuticleI: A new method for the physical isolation of cuticle. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact